The research deal that is scheduled for three years will employ GlycoVaxyn’s bio-conjugation technology.
GlycoVaxyn co-founder and chief scientific officer Michael Wacker said bacterial pathogens existing in multiple pathogenic strains cause significant challenges for developing vaccines that target these strains.
"Our recombinant DNA-based vaccine technology is particularly well-suited for polyvalent conjugate vaccines and should make the development and commercialization of these vaccines more feasible and reliable," Wacker added.
GlycoVaxyn will partner with Crucell Holland, JPI’s affiliate, on the multi-valent vaccine development until proof-of-concept while JPI will look after later-stage studies and global commercialization.
According to the deal, GlycoVaxyn is eligible for upfront payment, milestone payments, royalties in addition to reimbursement of research and development expenses.
GlycoVaxyn chief executive officer Philippe Dro said, "This collaboration is a further confirmation of the position GlycoVaxyn is about to occupy in the vaccine development space."
Financial details of the transaction were not revealed.